Demonstrates high-affinity tumor imaging and targeted radiotherapy in preclinical models and cancer patients, highlighting its potential as a dual theranostic agent.
A suitable theranostic molecule targeting the fibroblast activation protein (FAP) might provide individualized and precise diagnostic and therapeutic solutions for patients with FAP-positive tumors. In this study, a FAP-targeted molecule, FAPI-JNU, was developed with picomolar affinity for FAP. [ 68 Ga]Ga/[ 177 Lu]Lu-FAPI-JNU was synthesized and verified by HPLC, demonstrating high radiochemical purity (>95%) and yield (>90%). Favorable biodistribution and tumor-targeting specificity of [ 68 Ga]Ga-FAPI-JNU were determined in tumor-bearing mice expressing FAP ( n = 4), with higher tumor uptake observed compared to [ 68 Ga]Ga-FAPI-46. Clinical PET/CT imaging with [ 68 Ga]Ga-FAPI-JNU showed superior detection of lymph node metastases, bone metastases, and recurrent lesions compared to [ 18 F]F-FDG ( n = 9). [ 177 Lu]Lu-FAPI-JNU demonstrated effective tumor targeting and inhibition of tumor development in tumor-bearing mice, with the high radio-dosage group (46 MBq/mouse, n = 6) showing significant antitumor efficacy compared to the blank control group. The developed radiopharmaceuticals, [ 68 Ga]Ga/[ 177 Lu]Lu-FAPI-JNU, show potential for clinical use in diagnostic imaging and tumor therapy through FAP targeting.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: